Here, we describe a case of a patient who developed Bing Neel syndrome as a secondary complication of Waldenström's macroglobulinemia and exhibited a remarkable response to Zanubrutinib, a second‐generation Bruton tyrosine kinase (BTK) inhibitor. The gene discussed is BTK; the disease is Waldenstrom macroglobulinemia.